Biotech Walloped On Clinton Drug Price Controls Threat
This article was originally published in Scrip
Executive Summary
It was déjà vu all over again on Wall Street on Sept. 21 when biotech stocks took a beating after a powerful Washington politician vowed to take action to control prescription drug prices – a whipping reminiscent of March 2014 after three Democratic lawmakers set off a frenzy by suggesting they may pursue a similar path when they called on Gilead Sciences to explain its $1,000-per-pill price for its hepatitis C virus (HCV) medicine Sovaldi (sofosbuvir).